Biotech
Syncell
Syncell raises $15M Series A at $75M valuation
Taipei, TaiwanDecember 1, 20241 min read
Total Raised
$15M
Valuation
$75M
Latest Round
Series A
Employees
60+
Syncell: Series A Funding Round
Syncell has successfully raised $15M in Series A funding, reaching a valuation of $75M.
Company Overview
Cell therapy manufacturing platform for regenerative medicine
Funding Details
The Series A round was led by Taiwania Capital, with participation from KdT Ventures.
Company Information
- Headquarters: Taipei, Taiwan
- Founded: 2020
- Employees: 60+
- Category: Biotech
Investment
Syncell plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Taiwania Capital: Verified investor in Series A
- KdT Ventures: Verified investor in Series A
Company Info
Headquarters
Taipei, Taiwan
Founded
2020
Team Size
60+
Last Round
$15M(Dec 2024)
Investors (2)
T
Taiwania CapitalLeadLead Investor
Verified investor in Series A
K
KdT VenturesInvestor
Verified investor in Series A
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min readβ’$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free